{"name":"NORDynamIC Study Group","slug":"nordynamic-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Peginterferon alfa-2a 40KD and Ribavirin","genericName":"Peginterferon alfa-2a 40KD and Ribavirin","slug":"peginterferon-alfa-2a-40kd-and-ribavirin","indication":"Chronic hepatitis C virus infection (genotype-dependent, now largely superseded by direct-acting antivirals)","status":"marketed"}]}],"pipeline":[{"name":"Peginterferon alfa-2a 40KD and Ribavirin","genericName":"Peginterferon alfa-2a 40KD and Ribavirin","slug":"peginterferon-alfa-2a-40kd-and-ribavirin","phase":"marketed","mechanism":"Peginterferon alfa-2a activates interferon-alpha receptors to enhance antiviral immunity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.","indications":["Chronic hepatitis C virus infection (genotype-dependent, now largely superseded by direct-acting antivirals)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}